Literature DB >> 17211828

Influence of Ki-ras-driven oncogenic transformation on the protein network of murine fibroblasts.

Christian V Recktenwald1, Simone Mendler, Rudolf Lichtenfels, Roland Kellner, Barbara Seliger.   

Abstract

Ki-ras gene mutations that specifically occur in codons 12, 13 and 61 are involved in the carcinogenesis of acute myeloid leukemia, melanoma and different carcinomas. In order to define potential mutation-specific therapeutic targets, stable transfectants of NIH3T3 cells carrying different Ki-ras4B gene mutations were generated. Wild type Ki-ras transformants, mock transfectants and parental cells served as controls. These in vitro model systems were systematically analyzed for their protein expression pattern using two-dimensional gel electrophoresis followed by mass spectrometry and/or protein sequencing. Using this approach, a number of target molecules that are differentially but coordinately expressed in the ras transfectants were identified next to other proteins that exhibit a distinct regulation pattern in the different cell lines analyzed. The differentially expressed proteins predominantly belong to the families of cytoskeletal proteins, heat shock proteins, annexins, metabolic enzymes and oxidoreductases. Their validation was assessed by real-time quantitative RT-PCR and/or Western blot analysis. Our results suggest that the Ki-ras-transformed cells represent a powerful tool to study Ki-ras gene mutation-driven protein expression profiles. In addition, this approach allows the discovery of ras-associated cellular mechanisms, which might lead to the identification of physiological targets for pharmacological interventions of the treatment of Ki-ras-associated human tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17211828     DOI: 10.1002/pmic.200600506

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  9 in total

1.  Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma.

Authors:  Barbara Seliger; Sven P Dressler; Ena Wang; Roland Kellner; Christian V Recktenwald; Friedrich Lottspeich; Francesco M Marincola; Maja Baumgärtner; Derek Atkins; Rudolf Lichtenfels
Journal:  Proteomics       Date:  2009-03       Impact factor: 3.984

2.  Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.

Authors:  Karthikeyan Subbarayan; Sandra Leisz; Claudia Wickenhauser; Daniel Bethmann; Chiara Massa; André Steven; Barbara Seliger
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

3.  HER-2/neu-mediated down-regulation of biglycan associated with altered growth properties.

Authors:  Christian V Recktenwald; Sandra Leisz; André Steven; Kousaku Mimura; Anja Müller; Jens Wulfänger; Rolf Kiessling; Barbara Seliger
Journal:  J Biol Chem       Date:  2012-05-11       Impact factor: 5.157

4.  Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.

Authors:  Sandra Leisz; Kristin Schulz; Susanne Erb; Peter Oefner; Katja Dettmer; Dimitrios Mougiakakos; Ena Wang; Francesco M Marincola; Franziska Stehle; Barbara Seliger
Journal:  Oncotarget       Date:  2015-05-10

5.  Personalizing colon cancer therapeutics: targeting old and new mechanisms of action.

Authors:  Christina Leah B Kline; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2013-08-21

6.  Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies.

Authors:  Anibal Bueno; Ian Morilla; Diego Diez; Aurelio A Moya-Garcia; José Lozano; Juan A G Ranea
Journal:  Oncotarget       Date:  2016-11-15

7.  Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.

Authors:  Karthikeyan Subbarayan; Chiara Massa; Sandra Leisz; André Steven; Daniel Bethmann; Katharina Biehl; Claudia Wickenhauser; Barbara Seliger
Journal:  Oncoimmunology       Date:  2022-04-28       Impact factor: 7.723

8.  High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling.

Authors:  Michael C Burns; Jennifer E Howes; Qi Sun; Andrew J Little; DeMarco V Camper; Jason R Abbott; Jason Phan; Taekyu Lee; Alex G Waterson; Olivia W Rossanese; Stephen W Fesik
Journal:  Anal Biochem       Date:  2018-02-11       Impact factor: 3.365

9.  Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study.

Authors:  M Horsch; C V Recktenwald; S Schädler; M Hrabé de Angelis; B Seliger; J Beckers
Journal:  Br J Cancer       Date:  2009-02-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.